Reuters logo
8 months ago
BRIEF-Intercept says European Commission grants Ocaliva marketing authorization
December 14, 2016 / 12:40 PM / 8 months ago

BRIEF-Intercept says European Commission grants Ocaliva marketing authorization

Dec 14 (Reuters) - Intercept Pharmaceuticals Inc

* European Commission grants Intercept's Ocaliva (obeticholic acid) marketing authorization for the treatment of primary biliary cholangitis

* Intercept Pharmaceuticals-as conditions of approval, co required to provide post-approval updates on safety, efficacy analyses for Ocaliva Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below